L. Gordon

发表

Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides.

David M. Wilson, P. Bamborough, C. Chung, 2012, Journal of medicinal chemistry.

Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).

David M. Wilson, P. Bamborough, R. Prinjha, 2012, Bioorganic & medicinal chemistry letters.

Application of Atypical Acetyl-Lysine Methyl Mimetics in the Development of Selective Inhibitors of the Bromodomain-Containing Protein 7 (BRD7)/Bromodomain-Containing Protein 9 (BRD9) Bromodomains.

Melanie V. Leveridge, P. Grandi, A. Michon, 2020, Journal of medicinal chemistry.

Direct Measurement of Intracellular Compound Concentration by RapidFire Mass Spectrometry Offers Insights into Cell Permeability

M. Hann, P. Artursson, A. Mateus, 2016, Journal of biomolecular screening.

6-[2-(4-Aryl-1-piperazinyl)ethyl]-2H-1,4-benzoxazin-3(4H)-ones: dual-acting 5-HT1 receptor antagonists and serotonin reuptake inhibitors.

S. Bromidge, L. Gordon, J. Watson, 2008, Bioorganic & medicinal chemistry letters.

Optimization of a Series of 2,3-Dihydrobenzofurans as Highly Potent, Second Bromodomain (BD2)-Selective, Bromo and Extra-Terminal Domain (BET) Inhibitors.

P. Grandi, I. Wall, James M. Woolven, 2021, Journal of medicinal chemistry.

Optimization of a Series of RIPK2 PROTACs.

Aditya R. Thawani, I. E. Smith, R. Nagilla, 2021, Journal of medicinal chemistry.

The Optimisation of Potent ATAD2 and CECR2 Bromodomain Inhibitors with an Atypical Binding Mode.

P. Bamborough, R. Prinjha, C. Chung, 2020, Journal of medicinal chemistry.

GSK789: A Selective Inhibitor of the First Bromodomains (BD1) of the Bromo and Extra Terminal Domain (BET) Proteins.

P. Grandi, P. Bamborough, R. Prinjha, 2020, Journal of medicinal chemistry.

1,3-Dimethyl Benzimidazolones Are Potent, Selective Inhibitors of the BRPF1 Bromodomain.

David J. Fallon, P. Grandi, A. Michon, 2014, ACS medicinal chemistry letters.

Discovery of the first potent, selective 5-hydroxytryptamine1D receptor antagonist.

C. Scott, S. Ward, L. Gordon, 2005, Journal of medicinal chemistry.

In vitro and in vivo characterization of the novel GABAB receptor positive allosteric modulator, 2-{1-[2-(4-chlorophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-7-yl]-2-piperidinyl}ethanol (CMPPE)

A. Capelli, M. Corsi, L. Gordon, 2011, Neuropharmacology.

Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition.

Andrew J. Bannister, Melanie V. Leveridge, S. Robson, 2016, Journal of medicinal chemistry.